Additionally, elevated SHP2 expression correlates with enhanced survival in advanced KRAS mutant NSCLC and serves as a predictor for the efficacy of PD-1/PD-L1 therapies (92). This evidence concerns the gene PTPN11 and non-small cell lung carcinoma.